menu
    • menu

    Company profile for Eisai Inc

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and help to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., the company has a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a ...
    At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and help to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., the company has a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Eisai IncUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 Metro Blvd, Nutley, NJ 07110
    Telephone
    Telephone
    +1 2016921100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://us.eisai.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/eisai/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/eisaius?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eisai Stays Confident In Anti-Tau Asset Amid J&J Setback In Tau
    Eisai Stays Confident In Anti-Tau Asset Amid J&J Setback In Tau

    05 Dec 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/eisai-still-confident-in-anti-tau-asset-as-j-j-becomes-latest-victim-in-spiraling-space

    BIOSPACE
    05 Dec 2025
    Share Share
    Eisai Reveals Extended Benefits Of LEQEMBI In Early Alzheimer
    Eisai Reveals Extended Benefits Of LEQEMBI In Early Alzheimer

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3199431/0/en/Eisai-Presents-New-Data-on-the-Continued-and-Expanding-Benefit-of-LEQEMBI-lecanemab-irmb-Maintenance-Treatment-in-Early-Alzheimer-s-Disease-at-the-Clinical-Trials-on-Alzheimer-s-Di.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    Eisai Present Etalanetug (E2814) Data At CTAD 2025
    Eisai Present Etalanetug (E2814) Data At CTAD 2025

    01 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eisai-presents-new-data-on-anti-tau-antibody-etalanetug-e2814-at-ctad-2025-302629668.html

    PR NEWSWIRE
    01 Dec 2025
    Share Share
    Eisai Files NDA for Subcutaneous LEQEMBI in Early AD in Japan
    Eisai Files NDA for Subcutaneous LEQEMBI in Early AD in Japan

    27 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/28/3195968/0/en/Eisai-Submits-New-Drug-Application-for-Subcutaneous-Formulation-of-LEQEMBI-for-the-Treatment-of-Early-Alzheimer-s-Disease-in-Japan.html

    GLOBENEWSWIRE
    27 Nov 2025
    Share Share
    Eisai Files sBLA with FDA for LEQEMBI in Early Alzheimer Diseases
    Eisai Files sBLA with FDA for LEQEMBI in Early Alzheimer Diseases

    25 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eisai-completes-rolling-submission-to-us-fda-for-leqembi-iqlik-lecanemab-irmb-supplemental-biologics-license-application-as-a-subcutaneous-starting-dose-for-the-treatment-of-early-alzheimers-disease-under-fast-track-status-302625100.html

    PR NEWSWIRE
    25 Nov 2025
    Share Share
    Eisai To Share Lecanemab Data At 18th CTAD Conference
    Eisai To Share Lecanemab Data At 18th CTAD Conference

    18 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eisai-to-present-data-on-lecanemab-continued-treatment-subcutaneous-initiation-dosing-and-real-world-experience-at-the-18th-clinical-trials-on-alzheimers-disease-ctad-conference-302617382.html

    PR NEWSWIRE
    18 Nov 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Eisai Inc and get a quotation

    Eisai Inc is a supplier offers 3 products (APIs, Excipients or Intermediates).

    Find a price of MOH040 bulk with DMF offered by Eisai Inc

    Find a price of INTERLEUKIN-2 DIPHTHERIA TOXIN FUSION PROTEIN (DAB 389 IL-2) bulk offered by Eisai Inc

    Find a price of Eperisone Hydrochloride bulk offered by Eisai Inc

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search